Skip to main content
. 2022 Oct 4;14:949361. doi: 10.3389/fnagi.2022.949361

TABLE 4.

Distinct contributions of CB1R or CB2R on stress and neuropathology in AD transgenic rodent models.

Neuropathology Selective CB1 agonist/CB1-dependent effects Selective CB2 agonist/CB2-dependent effects
Aβ 42 and Tau-p APP/PS1xCB1-KO (heterozygous)
-NO EFFECT on Ab density or plaque deposition
↓ PSD-95 Expression (Aso et al., 2018).		 AbPP/PS1
JWH-133 Treatment at pre-symptomatic stages:
↓ tau phosphorylation at Th181
-NO EFFECT on Ab42 production/deposition in cortex or hippocampus (Aso et al., 2013).
APP/PS1xCB2-KO (HOMOZYGOUS)
↑O (HOMOZ Ab42 deposition
↑deposit Ab40 (Aso et al., 2016).
Inflammation, neuronal injury APP/PS1xCB1-KO (homozygous)
-CB1-KO drastically reduced survival of APP/PS1 Mice.
(Aso et al., 2018).		 AbPP/PS1
JWH-133 Treatment at pre-symptomatic stages:
↓microglial reactivity
↓proinflammatory cytokine expression (IL-1b, IL-6, TNF-a, IFNg)
↑ INACTIVE GSK3b
↓ active p38, SAPK/JNK (Aso et al., 2013).
APP/PS1xCB2-KO (homozygous)
NO EFFECT on viability of APP/PS1 Mice (Aso et al., 2016).
Cognition/BPSD APP/PS1xCB1-KO (heterozygous)
Accelerated memory impairment (Aso et al., 2018).		 AbPP/PS1
JWH-133 Treatment at pre-symptomatic stages:
Enhanced learning and memory
(Aso et al., 2013)
APP/PS1xCB2-KO (HOMOZYGOUS)
-Attenuated the beneficial cognitive effects of cannabis (Aso et al., 2016).